Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report

Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with relapsed metastatic melanoma previously treated with pembrolizumab who developed grade 3 immune-related renal toxicity after reintroduction of the same ICI, secondary to acute interstitial nephritis with accompanying high PR3-antineutrophil cytoplasmic antibody titer. The patient improved after steroid treatment and discontinuation of pembrolizumab. This case highlights the importance of not excluding ICI-related nephrotoxicity as a possible cause of renal failure, including in those who previously tolerated ICI treatment, since it is a treatable entity.

Automated summary

Renal toxicity from ICIs can present as acute interstitial nephritis with highly variable timing. This case study presents a male patient who developed grade 3 immune-related renal toxicity after reusing the same ICI, but improved after steroid treatment and discontinuation of the medication.